2,3,7,8‑tetrachlorodibenzo‑p‑dioxin suppresses the growth of human colorectal cancer cells in vitro: Implication of the aryl hydrocarbon receptor signaling

Yamaguchi,Masayoshi; Hankinson,Oliver

doi:10.3892/ijo.2019.4703

2,3,7,8‑tetrachlorodibenzo‑p‑dioxin suppresses the growth of human colorectal cancer cells in vitro: Implication of the aryl hydrocarbon receptor signaling

Authors:
- Masayoshi Yamaguchi
- Oliver Hankinson
View Affiliations

Affiliations: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 700 Tiverton Avenue, Los Angeles, CA 90095‑1732, USA, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 700 Tiverton Avenue, Los Angeles, CA 90095‑1732, USA
Published online on: January 30, 2019 https://doi.org/10.3892/ijo.2019.4703
Pages: 1422-1432

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human colorectal cancer is the third most common cancer disease with a 5‑year survival rate of 55% in USA in 2016. The investigation to identify novel biomarker factors with molecular classification may provide notable clinical information to prolong the survival of patients with colorectal cancer. The aryl hydrocarbon receptor (AHR) binds the AHR nuclear translocator in the cytoplasm of various types of cells, including liver cells, and then binds to the xenobiotic responsive element on various genes. AHR was initially discovered via its ligand, the polychlorinated hydrocarbon, 2,3,7,8‑tetrachlorodibenzo‑p‑dioxin (TCDD). The present study was undertaken to determine whether TCDD, an agonist of AHR signaling, impacts the growth of RKO human colorectal cancer cells in vitro. Treatment with TCDD (0.1‑100 nM) revealed suppressive effects on colony formation and proliferation of RKO cells, and stimulated death of these cells with subconfluence. These effects of TCDD were abolished by pretreatment with CH223191, an inhibitor of AHR signaling. Western blot analysis demonstrated that TCDD treatment decreased AHR levels and elevated cytochrome P450 family 1 subfamily A member 1 (CYP1A1) levels, indicating a stimulation of AHR signaling. TCDD treatment caused an increase in nuclear factor‑κB p65 and β‑catenin levels, although it did not have an effect on Ras levels. Notably, TCDD treatment increased the levels of p53, retinoblastoma, p21 and regucalcin, which are depressors of carcinogenesis. Additionally, action of TCDD on cell proliferation and death were not revealed in regucalcin‑overexpressing RKO cells, and regucalcin overexpression depressed AHR signaling associated with CYP1A1 expression. Thus, AHR signaling suppresses the growth of colorectal cancer cells, indicating a role as a significant targeting molecule for colorectal cancer.

View Figures

View References

1	Medema JP and Vermeulen L: Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature. 474:318–326. 2011. View Article : Google Scholar : PubMed/NCBI
2	Porter MG and Stoeger SM: Atypical colorectal neoplasms. Surg Clin North Am. 97:641–656. 2017. View Article : Google Scholar : PubMed/NCBI
3	American Cancer Society: Cancer facts and figures 2016. American Cancer Society; Atlanta, GA: 2016, https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html. Accessed January 24, 2017.
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
5	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
6	Alnabulsi A and Murray GI: Integrative analysis of the colorectal cancer proteome: Potential clinical impact. Expert Rev Proteomics. 13:1–11. 2016. View Article : Google Scholar
7	Alnabulsi A, Swan R, Cash B, Alnabulsi A and Murray GI: The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance. Br J Cancer. 116:1612–1620. 2017. View Article : Google Scholar : PubMed/NCBI
8	Carini F, Mazzola M, Rappa F, Jurjus A, Geagea AG, Al Kattar S, Bou-Assi T, Jurjus R, Damiani P, Leone A, et al: Colorectal carcinogenesis: Role of oxidative stress and antioxidants. Anticancer Res. 37:4759–4766. 2017.PubMed/NCBI
9	Colussi D, Brandi G, Bazzoli F and Ricciardiello L: Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int J Mol Sci. 14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kudryavtseva AV, Lipatova AV, Zaretsky AR, Moskalev AA, Fedorova MS, Rasskazova AS, Shibukhova GA, Snezhkina AV, Kaprin AD, Alekseev BY, et al: Important molecular genetic markers of colorectal cancer. Oncotarget. 7:53959–53983. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hankinson O: The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol. 35:307–340. 1995. View Article : Google Scholar : PubMed/NCBI
12	Hankinson O: Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys. 433:379–386. 2005. View Article : Google Scholar
13	Denison MS and Nagy SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 43:309–334. 2003. View Article : Google Scholar : PubMed/NCBI
14	Nguyen LP and Bradfield CA: The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 21:102–116. 2008. View Article : Google Scholar
15	Ronnekleiv-Kelly SM, Nukaya M, Díaz-Díaz CJ, Megna BW, Carney PR, Geiger PG and Kennedy GD: Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells. Cancer Lett. 370:91–99. 2016. View Article : Google Scholar :
16	Ikuta T, Kurosumi M, Yatsuoka T and Nishimura Y: Tissue distribution of aryl hydrocarbon receptor in the intestine: Implication of putative roles in tumor suppression. Exp Cell Res. 343:126–134. 2016. View Article : Google Scholar : PubMed/NCBI
17	Pastorková B, Vrzalová A, Bachleda P and Dvořák Z: Hydroxystilbenes and methoxystilbenes activate human aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes. Food Chem Toxicol. 103:122–132. 2017. View Article : Google Scholar : PubMed/NCBI
18	Safe S, Lee SO and Jin UH: Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci. 135:1–16. 2013. View Article : Google Scholar : PubMed/NCBI
19	Mulero-Navarro S and Fernandez-Salguero PM: New trends in aryl hydrocarbon receptor biology. Front Cell Dev Biol. 4:452016. View Article : Google Scholar : PubMed/NCBI
20	Stejskalova L and Pavek P: The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol. 12:715–730. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nukaya M, Moran S and Bradfield CA: The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc Natl Acad Sci USA. 106:4923–4928. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui LC, Bats AS, Fournet JC, Fernandez-Salguero P, Aggerbeck M, Lotersztajn S, et al: Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin. Toxicol Sci. 137:114–124. 2014. View Article : Google Scholar
23	Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, Van Winkle L, Matsumura F and Vogel CF: Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E^−/− mice. Arterioscler Thromb Vasc Biol. 31:1260–1267. 2011. View Article : Google Scholar : PubMed/NCBI
24	Brito JS, Borges NA, Esgalhado M, Magliano DC, Soulage CO and Mafra D: Aryl hydrocarbon receptor activation in chronic kidney disease: Role of uremic toxins. Nephron. 137:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
25	Esser C: The aryl hydrocarbon receptor in immunity: Tools and potential. Methods Mol Biol. 1371:239–257. 2016. View Article : Google Scholar
26	Murray IA, Patterson AD and Perdew GH: Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer. 14:801–814. 2014. View Article : Google Scholar
27	Barouki R, Coumoul X and Fernandez-Salguero PM: The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 581:3608–3615. 2007. View Article : Google Scholar : PubMed/NCBI
28	Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L and Schwarz M: A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64:4707–4710. 2004. View Article : Google Scholar : PubMed/NCBI
29	Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y and Puga A: The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 70:212–220. 2010. View Article : Google Scholar
30	Mathew LK, Simonich MT and Tanguay RL: AHR-dependent misregulation of Wnt signaling disrupts tissue regeneration. Biochem Pharmacol. 77:498–507. 2009. View Article : Google Scholar :
31	Jackson DP, Li H, Mitchell KA, Joshi AD and Elferink CJ: Ah receptor-mediated suppression of liver regeneration through NC-XRE-driven p21^Cip1 expression. Mol Pharmacol. 85:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
32	Yamaguchi M and Hankinson O: 2,3,7,8-Tetrachlorodibenzo- p-dioxin suppresses the growth of human liver cancer HepG2 cells in vitro: Involvement of cell signaling factors. Int J Oncol. 53:1657–1666. 2018.PubMed/NCBI
33	Harper PA, Prokipcak RD, Bush LE, Golas CL and Okey AB: Detection and characterization of the Ah receptor for 2,3,7,8-tetra-chlorodibenzo-p-dioxin in the human colon adenocarcinoma cell line LS180. Arch Biochem Biophys. 290:27–36. 1991. View Article : Google Scholar : PubMed/NCBI
34	Megna BW, Carney PR, Nukaya M, Geiger P and Kennedy GD: Indole-3-carbinol induces tumor cell death: Function follows form. J Surg Res. 204:47–54. 2016. View Article : Google Scholar : PubMed/NCBI
35	Megna BW, Carney PR, Depke MG, Nukaya M, McNally J, Larsen L, Rosengren RJ and Kennedy GD: The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer. J Surg Res. 213:16–24. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wohak LE, Krais AM, Kucab JE, Stertmann J, Øvrebø S, Seidel A, Phillips DH and Arlt VM: Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol. 90:291–304. 2016. View Article : Google Scholar :
37	Li W, Harper PA, Tang BK and Okey AB: Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol. 56:599–612. 1998. View Article : Google Scholar : PubMed/NCBI
38	Xie G and Raufman J-P: Role of the aryl hydrocarbon receptor in colon neoplasia. Cancers (Basel). 7. pp. 1436–1446. 2015, View Article : Google Scholar
39	Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J, Pettersson S, Pollenz RS, Sakaki T, Hirokawa T, et al: Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in Apc^Min/+ mice with natural ligands. Proc Natl Acad Sci USA. 106:13481–13486. 2009. View Article : Google Scholar
40	Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
41	Wang K, Li Y, Jiang YZ, Dai CF, Patankar MS, Song JS and Zheng J: An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells. Cancer Lett. 340:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
42	Misawa H, Inagaki S and Yamaguchi M: Suppression of cell proliferation and deoxyribonucleic acid synthesis in the cloned rat hepatoma H4-II-E cells overexpressing regucalcin. J Cell Biochem. 84:143–149. 2001. View Article : Google Scholar : PubMed/NCBI
43	Yamaguchi M, Osuka S and Murata T: Prolonged survival of patients with colorectal cancer is associated with a higher regucalcin gene expression: Overexpression of regucalcin suppresses the growth of human colorectal carcinoma cells in vitro. Int J Oncol. 53:1313–1322. 2018.PubMed/NCBI
44	Yamaguchi M and Daimon Y: Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: Involvement of intracellular signaling factors and cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005. View Article : Google Scholar : PubMed/NCBI
45	Izumi T and Yamaguchi M: Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-alpha or thapsigargin. J Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
46	Yamaguchi M and Isogai M: Tissue concentration of calcium-binding protein regucalcin in rats by enzyme-linked immunoadsorbent assay. Mol Cell Biochem. 122:65–68. 1993. View Article : Google Scholar : PubMed/NCBI
47	Choi E-Y, Lee H, Dingle RWC, Kim KB and Swanson HI: Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor. Mol Pharmacol. 81:3–11. 2012. View Article : Google Scholar :
48	Tsurusaki Y and Yamaguchi M: Role of regucalcin in liver nuclear function: Binding of regucalcin to nuclear protein or DNA and modulation of tumor-related gene expression. Int J Mol Med. 14:277–281. 2004.PubMed/NCBI
49	Yamaguchi M: Suppressive role of regucalcin in liver cell proliferation: Involvement in carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
50	Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M and Murata T: Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol. 48:1955–1964. 2016. View Article : Google Scholar : PubMed/NCBI
51	Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M and Murata T: Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. Int J Oncol. 49:1686–1694. 2016. View Article : Google Scholar : PubMed/NCBI
52	Nejak-Bowen KN, Zeng G, Tan X, Cieply B and Monga SP: Beta-catenin regulates vitamin C biosynthesis and cell survival in murine liver. J Biol Chem. 284:28115–28127. 2009. View Article : Google Scholar : PubMed/NCBI
53	Kochhar A, Kopelovich L, Sue E, Guttenplan JB, Herbert BS, Dannenberg AJ and Subbaramaiah K: p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling. Cancer Prev Res (Phila). 7:596–606. 2014. View Article : Google Scholar
54	Yamaguchi M: Role of regucalcin in cell nuclear regulation: Involvement as a transcription factor. Cell Tissue Res. 354:331–341. 2013. View Article : Google Scholar : PubMed/NCBI